Effects of Intranasal Insulin Administration on Tissue Specific Insulin Sensitivity
NCT ID: NCT02933645
Last Updated: 2018-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2016-04-30
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study, the changes in tissue-specific insulin sensitivity and glucose uptake will be investigated by using glucose-analogue radiotracer (\[18F\]-fluorodeoxyglucose) with positron emission tomography (PET) imaging during insulin stimulation. Ten healthy males are studied, each receiving nasal sprays containing insulin or placebo in a randomized order on two separate days. After spray administration, glucose uptake in skeletal muscle, liver, subcutaneous and visceral adipose tissue, myocardium, intestines, brown adipose tissue and brain assessed by PET imaging and glucose uptake in these tissues is analyzed. Endogenous glucose production is calculated facilitating the measurements glucose and radiotracer uptake in tissues and tracer loss into urine.
As skeletal muscle consumes most of the glucose available, it is likely that administration of insulin sprays will result in an increased uptake in this tissue. Some increase in glucose uptake might also be seen in other tissue types after insulin spray versus placebo spray administration.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase
NCT04028960
Intranasal Insulin for Prevention of Type 1 Diabetes
NCT00223613
Safety Study of Intranasal Insulin in Type 1 Diabetes and Diabetic Peripheral Neuropathy
NCT01469559
Dose-Finding Study of Intranasal Insulin in Healthy Participants Insulin in Healthy Participants
NCT05062785
Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age
NCT06434038
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
SAMPLE SIZE:
A total of ten (n=10) healthy males are planned to be included, and the study is conducted with a cross-over design with each subject being investigated twice, once using intranasal insulin and once using intranasal placebo in single-blinded randomized order.
SCREENING VISIT/ELIGIBILITY:
Main inclusion and exclusion criteria will be evaluated at a screening visit. This visit will include a frequently-sampled 75 g oral glucose tolerance test as well as anthropometric measurements and clinical examination.
PET STUDY VISITS:
On the PET study days two cannulas will be inserted, one in a radial or an antecubital vein for tracer injection and infusion of glucose and insulin, another in the opposite radial or antecubital vein for blood sampling. The arm where the samples are taken will be kept warm to obtain arterialized venous blood. The subjects will rest in supine position on the PET/CT scanner bed during the study.
HYPERINSULINEMIC EUGLYCEMIC CLAMP:
Whole-body insulin sensitivity will be assessed by hyperinsulinemic euglycemic clamp with an primed insulin infusion rate of 0.25 mU/kg/min. To maintain the glucose level at 5.0 mmol/l intravenous glucose infusion is administered individually as needed to maintain euglycemia.
NASAL SPRAY ADMINISTRATION:
After 30 minutes of intravenous insulin infusion, the subjects will receive either 160 IU human insulin or placebo intranasally. The small amount of insulin known to be absorbed into circulation after the insulin nasal spray will be mimicked on placebo day. Therefore subjects will be administered 2.5 mU/kg of additional intravenous insulin over 15 minutes together with placebo spray administration.
LABORATORY SAMPLES:
To verify comparable insulin levels in circulation during the study, serum insulin and C-peptide levels will be determined in fasting state, and repeatedly throughout the experiment.
BLINDING:
The clinician and the study nurse are aware which spray is given, but subjects are blinded and additional insulin infusion on placebo day is done in a manner that the subjects remain blinded. The sprays are given on a randomized order. The randomization code was generated by a statistician using SAS, version 9.3 for Windows. The randomization block size was four and the method was permuted block randomization. The randomization was done for 16 subjects in case of discontinuations.
HEART RATE VARIABILITY:
Heart rate variability is recorded to evaluate changes in autonomous nervous system activity after spray administration on both visits. Polar RS800CX heart rate monitor (Polar Electro Ltd., Kempele, Finland) with two electrodes is used.
FDG-PET-IMAGING:
70 minutes after the start of clamp and 40 minutes after the application of nasal sprays the positron emission tomography (PET) scanning is started with the injection of glucose-analogue tracer labeled with positron-emitting fluorine-18 (\[18F\]-fluorodeoxyglucose, \[18F\]-FDG). PET/CT, GE DiscoveryTM ST System (General Electric Medical Systems, Milwaukee, WI, USA) with final resolution of 3.75 mm in PET images is used. All data will be corrected for dead-time, decay and measured photon attenuation. Dynamic PET-scans will be reconstructed with iterative reconstruction method. Radiotracer \[18F\]-FDG is produced in the PET Centre radiochemistry laboratory. Plasma radioactivity is measured with an automatic gamma counter by a medical technologist in the laboratory of the Turku PET Centre (Wizard 1480 3", Wallac, Turku, Finland).
PET-IMAGE ANALYSIS:
To determine tissue-specific glucose uptake during insulin stimulation from PET data, time-activity-curves of tissue activity and activity measured from plasma during the scanning are analysed graphically to define tracer's fractional uptake (Ki). To calculate glucose uptake rate (reported as µmol/kg/min), Ki is multiplied with plasma glucose level, divided with a constant that accounts for the differences in transport and dephosphorylation rates between D-glucose and FDG (lumped constant, LC) and divided with tissue specific gravity. Based on previous studies the LC is 1,2 for skeletal muscle; 1,0 for heart and liver; 1,14 for adipose tissue; 1,1 for intestines and 0,8 for brain. After the PET/CT an urine sample will be collected to quantify endogenous glucose production (EGP). This will be determined by subtracting urine loss and glucose infusion rate from rate of glucose disappearance.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Insulin nasal spray
Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain fast-acting human insulin Actrapid (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.
30 min before spray administration a hyperinsulinemic euglycemic clamp will be started and continued for 170 minutes. 40 min after spray administration \[18F\]-FDG PET-CT scan lasting 100 min is started.
Actrapid
Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays or 160 IU of fast-acting human insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray.
[18F]-FDG PET-CT
All subjects will undergo two positron emission tomography (PET) studies. On both visits they are injected with 185 MBq \[18F\]-fluorodeoxyglucose and scanned with a combined PET and computed tomography scanner.
Hyperinsulinemic euglycemic clamp
All subjects will undergo two hyperinsulinemic euglycemic clamp studies. The insulin infusion will be administered intravenously at a steady rate of 0.25 mU/kg/min for approximately 170 minutes. Glucose will be administered intravenously as a 200 mg/ml fluid to at varying rate to maintain euglycemia.
Placebo nasal spray
Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd,Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd,Denmark) over 15 min.
30 min before spray administration a hyperinsulinemic euglycemic clamp will be started and continued for 170 minutes. 40 min after spray administration \[18F\]-FDG PET-CT scan lasting 100 min is started.
Placebo
Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.
[18F]-FDG PET-CT
All subjects will undergo two positron emission tomography (PET) studies. On both visits they are injected with 185 MBq \[18F\]-fluorodeoxyglucose and scanned with a combined PET and computed tomography scanner.
Hyperinsulinemic euglycemic clamp
All subjects will undergo two hyperinsulinemic euglycemic clamp studies. The insulin infusion will be administered intravenously at a steady rate of 0.25 mU/kg/min for approximately 170 minutes. Glucose will be administered intravenously as a 200 mg/ml fluid to at varying rate to maintain euglycemia.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Actrapid
Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays or 160 IU of fast-acting human insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray.
Placebo
Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.
[18F]-FDG PET-CT
All subjects will undergo two positron emission tomography (PET) studies. On both visits they are injected with 185 MBq \[18F\]-fluorodeoxyglucose and scanned with a combined PET and computed tomography scanner.
Hyperinsulinemic euglycemic clamp
All subjects will undergo two hyperinsulinemic euglycemic clamp studies. The insulin infusion will be administered intravenously at a steady rate of 0.25 mU/kg/min for approximately 170 minutes. Glucose will be administered intravenously as a 200 mg/ml fluid to at varying rate to maintain euglycemia.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Fasting plasma glucose less than 6.1 mmol/l
3. Normal 2-hour oral glucose tolerance test (OGTT)
Exclusion Criteria
2. History of anorexia nervosa or bulimia
3. Smoking of tobacco, taking of snuffs, or use of narcotics
4. Abusive use of alcohol
5. Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results
20 Years
35 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Tuebingen
OTHER
Turku University Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pirjo Nuutila, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Turku University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Turku PET Centre
Turku, , Finland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Heni M, Wagner R, Kullmann S, Veit R, Mat Husin H, Linder K, Benkendorff C, Peter A, Stefan N, Haring HU, Preissl H, Fritsche A. Central insulin administration improves whole-body insulin sensitivity via hypothalamus and parasympathetic outputs in men. Diabetes. 2014 Dec;63(12):4083-8. doi: 10.2337/db14-0477. Epub 2014 Jul 15.
Heni M, Kullmann S, Preissl H, Fritsche A, Haring HU. Impaired insulin action in the human brain: causes and metabolic consequences. Nat Rev Endocrinol. 2015 Dec;11(12):701-11. doi: 10.1038/nrendo.2015.173. Epub 2015 Oct 13.
Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci. 2002 Jun;5(6):514-6. doi: 10.1038/nn849. No abstract available.
DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979 Sep;237(3):E214-23. doi: 10.1152/ajpendo.1979.237.3.E214.
Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985 Dec;5(4):584-90. doi: 10.1038/jcbfm.1985.87.
Peltoniemi P, Lonnroth P, Laine H, Oikonen V, Tolvanen T, Gronroos T, Strindberg L, Knuuti J, Nuutila P. Lumped constant for [(18)F]fluorodeoxyglucose in skeletal muscles of obese and nonobese humans. Am J Physiol Endocrinol Metab. 2000 Nov;279(5):E1122-30. doi: 10.1152/ajpendo.2000.279.5.E1122.
Botker HE, Bottcher M, Schmitz O, Gee A, Hansen SB, Cold GE, Nielsen TT, Gjedde A. Glucose uptake and lumped constant variability in normal human hearts determined with [18F]fluorodeoxyglucose. J Nucl Cardiol. 1997 Mar-Apr;4(2 Pt 1):125-32. doi: 10.1016/s1071-3581(97)90061-1.
Iozzo P, Jarvisalo MJ, Kiss J, Borra R, Naum GA, Viljanen A, Viljanen T, Gastaldelli A, Buzzigoli E, Guiducci L, Barsotti E, Savunen T, Knuuti J, Haaparanta-Solin M, Ferrannini E, Nuutila P. Quantification of liver glucose metabolism by positron emission tomography: validation study in pigs. Gastroenterology. 2007 Feb;132(2):531-42. doi: 10.1053/j.gastro.2006.12.040. Epub 2006 Dec 21.
Virtanen KA, Peltoniemi P, Marjamaki P, Asola M, Strindberg L, Parkkola R, Huupponen R, Knuuti J, Lonnroth P, Nuutila P. Human adipose tissue glucose uptake determined using [(18)F]-fluoro-deoxy-glucose ([(18)F]FDG) and PET in combination with microdialysis. Diabetologia. 2001 Dec;44(12):2171-9. doi: 10.1007/s001250100026.
Honka H, Makinen J, Hannukainen JC, Tarkia M, Oikonen V, Teras M, Fagerholm V, Ishizu T, Saraste A, Stark C, Vahasilta T, Salminen P, Kirjavainen A, Soinio M, Gastaldelli A, Knuuti J, Iozzo P, Nuutila P. Validation of [18F]fluorodeoxyglucose and positron emission tomography (PET) for the measurement of intestinal metabolism in pigs, and evidence of intestinal insulin resistance in patients with morbid obesity. Diabetologia. 2013 Apr;56(4):893-900. doi: 10.1007/s00125-012-2825-5. Epub 2013 Jan 20.
Wu HM, Bergsneider M, Glenn TC, Yeh E, Hovda DA, Phelps ME, Huang SC. Measurement of the global lumped constant for 2-deoxy-2-[18F]fluoro-D-glucose in normal human brain using [15O]water and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography imaging. A method with validation based on multiple methodologies. Mol Imaging Biol. 2003 Jan-Feb;5(1):32-41. doi: 10.1016/s1536-1632(02)00122-1.
Iozzo P, Gastaldelli A, Jarvisalo MJ, Kiss J, Borra R, Buzzigoli E, Viljanen A, Naum G, Viljanen T, Oikonen V, Knuuti J, Savunen T, Salvadori PA, Ferrannini E, Nuutila P. 18F-FDG assessment of glucose disposal and production rates during fasting and insulin stimulation: a validation study. J Nucl Med. 2006 Jun;47(6):1016-22.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-005392-24
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
T210/2015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.